Better plants with no DNA fiddling? Yes, scientists say

| December 8, 2015

article image
They were, the report says, “able to definitively show that Cas9 RNPs can be used to genetically modify plants,” which Jin-So Kim says “paves the way for the widespread use of RNA-guided genome editing in plant biotechnology and agriculture.” This could be revolutionary for the future of the seed industry, they say, by enabling production of plants that are heartier and more suited to climate change. In addition, it’s cheaper, faster, and more accurate than previous breeding techniques, such as radiation-induced mutations.

Spotlight

Consociate Health

Consociate Health partners with employers to provide professional employee benefits administrative services. With plan members in 48 states and an unmatched access to a wide variety of analytical, educational and human resource tools, Consociate has proven solutions for employer sponsored benefit programs. Consociate administers traditional self-funded programs, captive health insurance programs, association health plans, multi employer welfare associations (Taft-Hartley), FSA's, HSA's, COBRA and many other employee benefits.

OTHER ARTICLES
MEDICAL

Better Purification and Recovery in Bioprocessing

Article | August 2, 2021

In the downstream portion of any bioprocess, one must pick through the dross before one can seize the gold the biotherapeutic that the bioprocess was always meant to generate. Unfortunately, the dross is both voluminous and various. And the biotherapeutic gold, unlike real gold, is corruptible. That is, it can suffer structural damage and activity loss. When discarding the dross and collecting the gold, bioprocessors must be efficient and gentle. They must, to the extent possible, eliminate contaminants and organic debris while ensuring that biotherapeutics avoid aggregation-inducing stresses and retain their integrity during purification and recovery. Anything less compromises purity and reduces yield. To purify and recover biotherapeutics efficiently and gently, bioprocessors must avail themselves of the most appropriate tools and techniques. Here, we talk with several experts about which tools and techniques can help bioprocessors overcome persistent challenges. Some of these experts also touch on new approaches that can help bioprocessors address emerging challenges.

Read More

5 Biotech Stocks Winning the Coronavirus Race

Article | August 2, 2021

There are quite a few companies that have found ways to grow their business during the ongoing COVID-19 pandemic. This is especially true for a number of biotechs now working on developing a potential treatment for, or vaccine against, the virus; shares of such companies have largely surged over the past couple of months. Although many of these treatments and vaccines are still have quite a way to go before they're widely available, it's still worth taking some time to look through what's going on in the COVID-19 space right now. Here are five biotech stocks that are leading the way when it comes to addressing COVID-19. Regeneron Pharmaceuticals (NASDAQ:REGN) wasn't among the initial wave of companies to announce a potential COVID-19 drug. However, investor excitement quickly sent shares surging when the company announced that its rheumatoid arthritis drug, Kevzara, could help treat COVID-19 patients.

Read More

Ruminating on Bioprocessing 4.0

Article | August 2, 2021

The Bioprocessing 4.0 concept seeks to apply automation and technology to the digital transformation of biologics manufacturing. As the paradigm moves forward, it faces barriers to its adoption, according to Eric Langer, president of BioPlan Associates. “Perhaps the greatest challenges involve unsecured links and adapting the applications to areas where automation is critically needed today,” says Langer. “Unresolved security issues could seriously affect a company’s data in a regulated environment, so they will need to have iron-clad anti-hacking protection in place. Unfortunately, cyber security is not yet a top focus for the industry.”

Read More

Cell Out? Lysate-Based Expression an Option for Personalized Meds

Article | August 2, 2021

Cell-free expression (CFE) is the practice of making a protein without using a living cell. In contrast with cell line-based methods, production is achieved using a fluid containing biological components extracted from a cell, i.e., a lysate. CFE offers potential advantages for biopharma according to Philip Probert, PhD, a senior scientist at the Centre for Process Innovation in the U.K.

Read More

Spotlight

Consociate Health

Consociate Health partners with employers to provide professional employee benefits administrative services. With plan members in 48 states and an unmatched access to a wide variety of analytical, educational and human resource tools, Consociate has proven solutions for employer sponsored benefit programs. Consociate administers traditional self-funded programs, captive health insurance programs, association health plans, multi employer welfare associations (Taft-Hartley), FSA's, HSA's, COBRA and many other employee benefits.

Events